科研队伍
殷昊

 

undefined

最后学位:博士 (PhD,美国科罗拉多大学医学中心)

职称职务:教授、博导

专业方向:遗传学、药学

研究方向:基因编辑、核酸药物

电子邮件:haoyin@whu.edu.cn

 

 

教育经历

1999-2003  南京大学生命科学学院,学士

2004-2010  美国科罗拉多大学医学中心 (University of Colorado Anschutz Medical Campus),博士

 

工作经历与任职

2010-2016  美国麻省理工学院 (Massachusetts Institute of Technology),博士后

2016-2018  美国福泰制药 (Vertex Pharmaceuticals),研究员

2018-          武汉大学医学研究院,教授

 

获奖情况

2009  国家优秀自费留学生奖学金

2009  Award for Outstanding Research, University of Colorado

2010  The American Society for Pharmacology and Experimental Therapeutics Best Abstract Award

2010  The American Society for Pharmacology and Experimental Therapeutics Travel Award

2012  MGH/Harvard Future Leaders in Cancer Research and Translational Medicine, MGH Cancer Center

2016  Travel Award, The 21st International Symposium on Microsomes and Drug Oxidations

2016  Meritorious Abstract Travel Award, American Society of Gene & Cell Therapy (ASGCT)

 

学术兼职

学术杂志审稿人:

Journal of the American Chemical Society (JACS)Nature Communications; Chemical ReviewsChemical ScienceMolecular TherapyNucleic Acids Research 30多种学术杂志。

学术杂志编委:

Toxicology Letters

 

研究领域

       基因编辑工具 (比如CRISPR系统) 可以在细胞和组织内精确的修改基因,因而其存在治疗甚至治愈很多无药可治的疾病的可能性, 比如遗传病,感染性疾病和癌症等。尽管在临床上以及其他应用上有巨大的潜力,但CRISPR系统作为蛋白和RNA复合体,其有效低脱靶的体内传输 (in vivo delivery) 是最大的难点之一。本课题组综合应用分子生物学,生物信息学,病毒学,模式动物,纳米科学和化学的手段来解决此难点,主要包括:

1、基因编辑系统的创新

2、新型基因药物载体的设计

 

发表论文、专利和学术报告概况

1、已在国际刊物发表和接收论文40篇,被 SCI 引用4000余次, H index 25。

2、多项研究成果被美国及国际主流媒体报道,被 Nature 系列杂志专文评述。

3、申请美国和国际专利6项,已获批准2项。

4、国际学术会议特邀报告10余次, 分论坛主持人1次。

 

代表性论文* 通讯作者、# 同等贡献)

1. Yin H*, Xue W*, Anderson DG*. Nature Reviews Clinical Oncology In press 2019.

2. Song CQ et al. DR Liu*, Yin H*, Xue W*. Nature Biomedical Engineering In press 2019.

3. Zhang HX, Zhang Y*, Yin H*. Molecular Therapy In press 2019.

4. Yin H#, Song CQ#, Suresh S, Kwan SY, Wu Q, Walsh S, Ding J, Bogorad RL, Zhu LJ, Wolfe SA, Koteliansky V, Xue W, Langer R, Anderson DG,Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nature Chemical Biology 2018, 14(3):311-316.

*Journal highlight: Nature Catalysis “Better guidance is cheaper”;Featured by BioCentury | Altering Cas9 and its guide for fewer off-target edits.

5. Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nature Biotechnology 2017, 35(12):1179-1187.

*Featured by VOICE of America / US Researchers Use Nanotech, Gene Editing to Edit Cholesterol Gene VICE / CRISPR Can Now Edit Genes Using Nanoparticles Instead of Viruses.

Yahoo News / CNBC / Nanotech, gene editing used to edit cholesterol gene-US study.

Genetic Engineering & Biotechnology News / CRISPR/Cas9 Delivery Goes Nano with Enhanced Guide RNA Fiercebiotech / MIT scientists propose a safer way to edit genes with CRISPR / MIT News / Science Daily / Bioscience Technology / Medical News Today/Business Insider UK / The Medical News / Phys.org.

6. Yin H, Kauffman KJ and Anderson DG. Delivery technologies for genome editing. Nature Reviews Drug Discovery 2017, 16(6): 387-399.

7. Yin H, Song CQ, Dorkin JR, Zhu L, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi M, Walsh S, Bogorad R, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe S, Langer R, Xue W and Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nature Biotechnology 2016,34(3):328-33.

*Featured by MIT News / Science Daily / Bioscience Technology / Medical News Today / Deutsches Ärzteblatt / Nanowerk / Nanotechnology Now /The Medical News / Phys.org.

8. Yin H#, Bogorad RL#, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V. RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. Journal of Hepatology 2016, 64(4):899-907.

9. Mou H, Kennedy Z, Anderson DG, Yin H*, and Xue W*, Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Medicine 2015, 7(1):53.

10. Yin H#, Xue W#, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 2014, 32(6):551-3.

*100 top stories of 2014 by Discover Magazine as “A Giant Step for Gene Surgery”.

*Top Ten Genetics Stories for 2014: Incredible Achievements, by the DNA Exchange.

*Journal highlight: Nature Medicine (CRISPR technology for gene therapy) | A cover story in Science–Business eXchange of Nature Publishing Group | BioTechniques.

*Featured by MIT News / The Independent: Front Page Headlines / Fox News / The Times of India / Science Daily / Medical daily / The Voice of Russia / Phys.org / F1000Prime Recommendation.

11. Xue W#, Chen S#, Yin H#, Tammela T, Joshi N, Papagiannakopoulos T, Cai W, Yang G, Bronson R, Crowley D, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014, 514(7522):380-4.

*Journal highlight: Hepatology (Cutting short the path to murine liver cancer models).

*Featured by MIT News / Science Daily / Medical Press / Newswise / F1000Prime Recommendation.

12. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nature Reviews Genetics 2014, 15(8):541-55.

13. Bogorad RL#, Yin H#, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nature Communications 2014, 5:3869.

*Journal highlight: Nature Reviews Gastroenterology & Hepatology (Loss of integrin β1 impairs liver regeneration and HCC progression).

14. Yin H, Cheng L, Holt M, Hail N, Jr., Maclaren R, Ju C, “Lactoferrin protects against acetaminophen-induced liver injury in mice”, Hepatology 2010,51(3):1007-16.

15. Yin H, Cheng L, Langenbach R, Ju C, “Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury”, Hepatology 2007,45(1):159-69.

 

发表著作

Book Chapter "Genome Editing for Genetic Lung Diseases" Pharmaceutical Inhalation Aerosol Technology, Third Edition.

 

上一条:张楹 下一条:肖锐

地 址:湖北省武汉市武昌区东湖路115号 邮政编码:430071 电 话:027-68750205  邮 箱:mri@whu.edu.cn

CopyRight © 2016  版权所有:武汉大学医学研究院